On February 27, 2020 Ryvu Therapeutics (WSE: RVU), a clinical stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, reported that data from its multiple oncology programs will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 24 to April 29, 2020, in San Diego, CA (Press release, Ryvu Therapeutics, FEB 27, 2020, View Source [SID1234554950]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data presented will include results from the small-molecule STING agonists, dual A2A/A2B adenosine receptors antagonist program, HPK1 inhibitors and SMARCA2 (BRM) degraders program.
Details of the poster presentations are as follows:
Title: In vivo and in vitro characterization of RVU330 best-in-class dual A2A/A2B adenosine receptor antagonist
Session Title: Immunomodulatory Agents and Interventions 2
Session Date and Time: Tuesday, April 28, 2020 1:30 PM – 5:00 PM (PST)
Location: Section 46
Poster Board Number: 15
Permanent Abstract Number: 5555
Title: Development of selective small molecule STING agonists suitable for systemic administration
Session Title: Immunomodulatory Agents and Interventions 1
Session Date and Time: Tuesday, April 28, 2020, 9:00 AM – 12:30 PM (PST)
Location: Poster Section 49
Poster Board Number: 27
Permanent Abstract Number: 4521A
Title: Development and characterization of small molecule HPK1 inhibitors
Session Title: Small Molecule Therapeutic Agents
Session Date and Time: Monday, April 27, 2020 9:00 AM – 12:30 PM (PST)
Location: Poster Section 31
Poster Board Number: 14
Permanent Abstract Number: 1947
Title: Development of novel, selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1) mutated tumors
Session Category: Molecular and Cellular Biology/Genetics
Session Title: Histone Modifications and Epigenomics
Session Date and Time: Tuesday, April 28, 2020 9:00 AM – 12:30 PM (PST)
Location: Poster Section 9
Poster Board Number: 15
Permanent Abstract Number: 3656
Presentations will be held at the San Diego Convention Center, Exhibit Halls A-F, in respective Poster Sections. Additional information is available at on the AACR (Free AACR Whitepaper) conference website View Source